Research On ESG Disclosure Issues And Countermeasures Of Baiyunshan Pharmaceutical

In recent years,as the concept of sustainable development has gained global popularity,the ESG performance of companies has gradually come under public scrutiny.Actively disclosing ESG-related information and proactively assuming their responsibilities in environmental protection and social governance have also become new elements for companies to enhance their competitiveness.However,the development of ESG in China has been short,there is no uniform disclosure standard,and the disclosure level of enterprises varies.As a basic industry related to the nation’s livelihood,the quality of ESG information disclosure in the pharmaceutical industry is not high,and there is still a lot that can be improvedd.This paper uses a literature research method,a case study method and a comparative analysis method.,and takes theories of stakeholders,information asymmetry,sustainable development and triple bottom line as the theoretical support,and on the basis of sorting out the development of domestic and foreign ESG information disclosure,selects Baiyunshan Medicine’s social responsibility report as the research object,takes GRI standard as the research perspective,analyzes Baiyunshan Medicine’s disclosure status in environment,social responsibility and corporate The current status of disclosure in environmental,social responsibility and corporate governance aspects of Baiyunshan Pharmaceuticals is analyzed,and problems in ESG disclosure are further proposed: single disclosure method,avoidance of negative information disclosure,insufficient stakeholder information disclosure,lack of quantitative indicators in disclosure,and lack of accountability and supervision in disclosure.In view of the problems of Baiyunshan Medicine,we analyze the reasons from both corporate and regulatory levels: weak awareness of disclosure,imperfect disclosure system and lack of ESG professionals at the corporate level;and inadequate government disclosure system,inadequate regulatory mechanism,lack of third-party auditing and insufficient stakeholder attention at the regulatory level.Finally,according to these reasons,we propose a corresponding solution measures:Companies should raise ESG information awareness,build ESG information disclosure system,and strengthen ESG information disclosure talents;the supervisory level should improve ESG information disclosure system norms,strengthen government supervision,increase third-party auditing,and strengthen media public opinion supervision.The analysis in this paper provides ideas for Baiyunshan Pharmaceutical to improve ESG information disclosure,and also provides some reference for ESG information disclosure in the whole pharmaceutical industry.